Alma Jiménez

发表

Discovery of aminobenzyloxyarylamides as κ opioid receptor selective antagonists: application to preclinical development of a κ opioid receptor antagonist receptor occupancy tracer.

D. McKinzie, S. D. Kahl, M. Statnick, 2011, Journal of medicinal chemistry.

A Novel Nociceptin Receptor Antagonist LY2940094 Inhibits Excessive Feeding Behavior in Rodents: A Possible Mechanism for the Treatment of Binge Eating Disorder

J. Pintar, M. Ansonoff, J. Witkin, 2016, The Journal of Pharmacology and Experimental Therapeutics.

A Novel, Orally Bioavailable Nociceptin Receptor Antagonist, LY2940094, Reduces Ethanol Self-Administration and Ethanol Seeking in Animal Models.

F. Weiss, K. Perry, J. Witkin, 2016, Alcoholism, clinical and experimental research.

Development of LC-MS/MS-based receptor occupancy tracers and positron emission tomography radioligands for the nociceptin/orphanin FQ (NOP) receptor.

S. D. Kahl, D. Mudra, M. Statnick, 2012, Journal of medicinal chemistry.

Discovery of a novel series of orally active nociceptin/orphanin FQ (NOP) receptor antagonists based on a dihydrospiro(piperidine-4,7'-thieno[2,3-c]pyran) scaffold.

D. McKinzie, S. D. Kahl, J. Witkin, 2014, Journal of medicinal chemistry.

Stereoselective synthesis of trans -2,3-disubstituted pyrrolidines via addition to N-acyliminium ions

C. Pedregal, Alma Jiménez, Paloma Vidal, 2006 .

Novel selective and potent 5-HT reuptake inhibitors with 5-HT1D antagonist activity: chemistry and pharmacological evaluation of a series of thienopyran derivatives.

J. Gilmore, C. Lamas, Nuria Díaz, 2004, Bioorganic & medicinal chemistry.

A novel class of AMPA receptor allosteric modulators. Part 1: design, synthesis, and SAR of 3-aryl-4-cyano-5-substituted-heteroaryl-2-carboxylic acid derivatives.

E. Nisenbaum, N. Rankl, Alma Jiménez, 2006, Bioorganic & medicinal chemistry letters.

A novel class of positive allosteric modulators of AMPA receptors: design, synthesis, and structure-activity relationships of 3-biphenyl-4-yl-4-cyano-5-ethyl-1-methyl-1H-pyrrole-2-carboxylic acid, LY2059346.

E. Nisenbaum, N. Rankl, Alma Jiménez, 2006, Bioorganic & medicinal chemistry letters.

LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders

D. McKinzie, Xia Li, J. Witkin, 2014, Neuropharmacology.

Preclinical findings predicting efficacy and side‐effect profile of LY2940094, an antagonist of nociceptin receptors

Janice W. Smith, D. McKinzie, J. Pintar, 2016, Pharmacology research & perspectives.

Structural insights into probe-dependent positive allosterism of the GLP-1 receptor

M. Vieth, B. Chau, T. S. Kobilka, 2020, Nature Chemical Biology.

Discovery of an Orally Efficacious Positive Allosteric Modulator of the Glucagon-like Peptide-1 Receptor.

F. Willard, Alma Jiménez, A. D. Showalter, 2021, Journal of Medicinal Chemistry.

A Novel Nociceptin Receptor Antagonist LY2940094 Inhibits Excessive Feeding Behavior in Rodents: A Possible Mechanism for the Treatment of Binge Eating Disorder

J. Pintar, M. Ansonoff, J. Witkin, 2016, The Journal of Pharmacology and Experimental Therapeutics.

Assignment of absolute configuration on the basis of the conformational effects induced by chiral derivatizing agents: the 2-arylpyrrolidine case.

H. Broughton, Nuria Díaz, C. Pedregal, 2007, Organic letters.

LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders

D. McKinzie, Xia Li, J. Witkin, 2014, Neuropharmacology.